• Tania Jain, Merav Bar, Ankit J Kansagra, Elise A Chong, Shahrukh K Hashmi, Sattva S Neelapu, Michael Byrne, Elad Jacoby, Aleksandr Lazaryan, Caron A Jacobson, Stephen M Ansell, Farrukh T Awan, Linda Burns, Veronika Bachanova, Catherine M Bollard, Paul A Carpenter, John F DiPersio, Mehdi Hamadani, Helen E Heslop, Joshua A Hill, Krishna V Komanduri, Craig A Kovitz, Hillard M Lazarus, Justin M Serrette, Mohamad Mohty, David Miklos, Arnon Nagler, Steven Z Pavletic, Bipin N Savani, Stephen J Schuster, Mohamed A Kharfan-Dabaja, Miguel-Angel Perales, and Yi Lin.
• Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; Hematologic Malignancies and Bone Marrow Transplantation Program, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.
• Biol. Blood Marrow Transplant. 2019 Dec 1; 25 (12): 2305-2321.

AbstractAxicabtagene ciloleucel (YESCARTA; Kite Pharma, a Gilead Company, Los Angeles CA) and tisagenlecleucel (KYMRIAH; Novartis Pharmaceuticals Corp., Basel, Switzerland) are two CD19-directed chimeric antigen receptor (CAR) T cell products currently approved by the US Food and Drug Administration; the European Medicines Agency; Health Canada; Ministry of Health, Labor and Welfare (Japan); and Therapeutic Goods Administration (Australia) for treatment of specific subtypes of relapsed/refractory aggressive B cell non-Hodgkin lymphoma (NHL). Although this approval has been transformative in the use of cellular immunotherapy in lymphoma, there are concerns regarding appropriate use of this novel therapy and of short- and long-term toxicities. To address these issues, representatives of the American Society of Transplantation and Cellular Therapy convened to recognize and address key issues surrounding the clinical application of CD19 CAR T cell therapy in B cell lymphomas, in collaboration with worldwide experts. The aim of this article is to provide consensus opinion from experts in the fields of hematopoietic cell transplantation, cellular immunotherapy, and lymphoma regarding key clinical questions pertinent to the use of CD19 CAR T cell products for the treatment of NHL. As the clinical practice using CAR T cells grows worldwide, we anticipate that this guidance will be relevant for hematology/oncology physicians who care for patients with lymphomas.Copyright © 2019 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights reserved.

13 keywords...

hide…